/

Palatin Technologies, Inc.

PTN US

PTN USPalatin Technologies, Inc.

United States Composite

2.22

USD

+0.22

(+11.00%)

-2.53EPS Dil.

-0.88P/E

25.88MMarket Cap

Next Earnings

September 20

Held by Insiders

6.58%

Held by Institutions

19.71%

Short % of Float

3.48%

YTD Yield

-56.86%

3Y Yield

-84.71%

Capital Structure

FRC

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

Shares Outstanding

Market Capitalization

Working Capital

FRC

•

in mil. unless spec.

Dec'22

Mar'23

Jun'23

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

- -

0.00%

400.00%

Net Income, GAAP

-55.68%

-31.06%

22.22%

Free Cash Flow

-213.74%

-333.91%

3.33%

Total Cash Common Dividend

- -

Total Equity

-80.65%

9.56%

-100.00%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.42

-1.06

-0.60

-1.47

-3.55

2022

-0.75

-0.91

-0.80

-1.34

-3.79

2023

-0.86

- -

-0.63

-0.91

-2.53

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Dr. Carl Spana Ph.D.
Full Time Employees: 33
Sector: Healthcare
Industry: Biotechnology
Address: Cedar Brook Corporate Center Cranbury NJ United States 08512
IPO Date: Oct 15, 1997
CIK: 0000911216
Website: palatin.com
Business: Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Company News

Dow Jones Newswires
19 days ago
Palatin Technologies 1Q Loss/Shr 48c >PTN
Dow Jones Newswires
a month ago
Palatin Technologies Shares Drop 13% After Private Placement Prices
Dow Jones Newswires
2 months ago
Palatin Technologies Shares Fall 10% After Wider-Than-Expected 4Q Loss
Dow Jones Newswires
2 months ago
Palatin Technologies 4Q Loss/Shr 91c >PTN
Dow Jones Newswires
4 months ago
Palatin Technologies Shares Climb 18% on UpScriptHealth Partnership
Dow Jones Newswires
7 months ago
Palatin Technologies 3Q Loss/Shr 63c >PTN

Company Description

CEO: Dr. Carl Spana Ph.D.
Full Time Employees: 33
Sector: Healthcare
Industry: Biotechnology
Address: Cedar Brook Corporate Center Cranbury NJ United States 08512
IPO Date: Oct 15, 1997
CIK: 0000911216
Website: palatin.com
Business: Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Company News

Dow Jones Newswires
19 days ago
Palatin Technologies 1Q Loss/Shr 48c >PTN
Dow Jones Newswires
a month ago
Palatin Technologies Shares Drop 13% After Private Placement Prices
Dow Jones Newswires
2 months ago
Palatin Technologies Shares Fall 10% After Wider-Than-Expected 4Q Loss
Dow Jones Newswires
2 months ago
Palatin Technologies 4Q Loss/Shr 91c >PTN
Dow Jones Newswires
4 months ago
Palatin Technologies Shares Climb 18% on UpScriptHealth Partnership
Dow Jones Newswires
7 months ago
Palatin Technologies 3Q Loss/Shr 63c >PTN